FIELD: medicine.
SUBSTANCE: invention refers to medicine. The method involves a sequence of the qualitative measurement of an HLDF cell differentiation factor in the patient suffering from a cardiovascular disease.
EFFECT: sequence provides preparing the valid specific and reproducible immunoenzyme test system enabling detecting a vascular system biomarker in blood serum both of healthy individuals, and of the patients suffering from vascular diseases.
2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULAR DIAGNOSTIC TECHNIQUE FOR PSYCHOSOMATIC FUNCTION STATE IN PATIENTS WITH DISCIRCULATORY ENCEPHALOPATHY | 2012 |
|
RU2531922C2 |
| METHOD FOR ASSESSING EFFICACY OF THERAPEUTIC AGENTS FOR IMPROVING INDIVIDUAL'S COGNITIVE FUNCTIONS | 2012 |
|
RU2532379C2 |
| METHOD FOR PREDICTION OF PRIMARY OPEN-ANGLE GLAUCOMA | 2012 |
|
RU2483306C1 |
| SCREENING TEST FOR DETERMINATION OF THE FUNCTIONAL ACTIVITY OF THE RAT COMPLEMENT SYSTEM | 2022 |
|
RU2786208C1 |
| METHOD OF PREDICTING SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE IN HUMAN BODY IN DISEASES | 2022 |
|
RU2808416C1 |
| METHOD FOR DETERMINING LYSIS MULTIPLE MODIFIED LOW DENSITY LIPOPROTEIN | 2015 |
|
RU2577719C1 |
| METHOD OF DETERMINING THE ACTIVITY OF THE CLASSICAL AND ALTERNATIVE PATHWAYS OF THE MOUSE COMPLEMENT SYSTEM | 2022 |
|
RU2800363C1 |
| METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
| METHOD AND SET FOR FUNCTIONAL ACTIVITY ENZYME-IMMUNOASSAY OF HUMAN COMPLEMENT FACTOR H | 2014 |
|
RU2565454C1 |
| METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 | 2023 |
|
RU2814496C1 |
